跳到正文
ECA GMP News·精选AI 评分77

USP 在药典论坛 51(6) 发布三份可提取物与浸出物章节草案,征求意见截止 2026 年 1 月 31 日

USP: Proposals for Extractables & Leachables

AI 导读

USP 在《药典论坛》51(6) 发布 <1664> 可提取物与浸出物系列的三份章节草案,征求意见截止 2026 年 1 月 31 日。其中 <1664.3> 局部眼用药品与 <1664.4> 局部及透皮给药药品为新增章节,<1664.1> 吸入与鼻用药品为修订版。<1664.1> 修订基于 2015 年 8 月 1 日生效版本,新增元素杂质、亚硝胺以及货架期内额外浸出物时间点的检测内容。

推荐理由

材料列出 USP <1664> 系列三份草案的章节编号、剂型范围与征求意见截止日期,便于读者定位对应章节。

正文 · 原文

The USP is expanding the Extractables and Leachables (E&Ls) chapter series <1664>. Following the previously published draft chapter for E&Ls in parenteral drug products (<1664.2>) three new drafts of USP's E&L chapters were just published in Pharmacopoeial Forum (PF) 51(6) . The comment deadline is 31 January 2026.The USP E&L chapter series <1664> thus now includes the following subsections: <1664.1> Assessment of Leachables in Orally Inhaled and Nasal Drug Products (Revision) <1664.2> Parenteral Drug Products (Intramuscular, Intravenous, and Subcutaneous) (New) <1664.3> Assessment of Leachables in Topical Ophthalmic Drug Products (New) <1664.4> Assessment of Leachables in Topical and Transdermal Drug Products (New)Background and UpdatesUSP chapter <1664> Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging/Delivery Systems and its subsections addresses leachables derived from two primary sources: process equipment used to produce the dosage form and container closure systems used to package the drug product. The discussion in the subsections is primarily devoted to organic leachables. For consideration of inorganic (i.e., elemental) leachables, general chapter <1664> is applicable.The proposal for <1664.1> is based on the version of the chapter official as of 1 August 2015. The revision addresses specific considerations for leachables in orally inhaled and nasal drug products, including metered-dose inhalers, nasal sprays, inhalation solutions, suspensions, sprays, and dry powder inhalers. The updates include sections on elemental impurities, nitrosamines, and testing of additional leachable time points over the shelf life. The new proposed chapter <1664.3> contains specific considerations for leachables in topical ophthalmic drug products, including solutions, suspensions, emulsions, and ointments. Chapter <1664.4> specifically addresses the unique considerations for leachables in topical and transdermal drug products, including patches, creams, gels, ointments, pastes, suspensions, lotions, foams, sprays, aerosols, and solutions. More information is available online in the Pharmacopeial Forum (PF).

来源:ECA GMP News · gmp-compliance.org